-
Six CRI-Funded Scientists on Dr. James P. Allison’s Impact on Their Lives and Careers
We spoke with six CRI-funded scientists who have worked in Allison’s lab about their experiences and the impact…
-
ASH18 Preview: Blood Cancer Immunotherapy Developments at 60th American Society of Hematology Meeting
The 2018 American Society of Hematology meeting will showcase a variety of basic and clinical advances in…
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
CICON18 Preview: Translating Science into Survival
Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…
